Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Modulation of alloreactivity using genetically modified T lymphocytes]

P Tiberghien1

  • 1Laboratoire de Thérapeutique Immuno-moléculaire, Etablissement de Transfusion Sanguine de Franche-Comté, Besançon.

Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of recent criteria changes for the deferral criteria specific to men who have sex with men in France.

Vox sanguinis·2024
Same author

[COVID-19: Still a place for the convalescent plasma? Focus on the immunocompromised patients].

La Revue de medecine interne·2023
Same author

Increasing unpaid plasma collection by blood establishments to ensure availability of plasma-derived medicinal products and blood components in Europe.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2021
Same author

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Rational and design of the T-STORHM Study: A prospective randomized trial comparing fresh whole blood to blood components for acutely bleeding trauma patients.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2019
Same author

International haemovigilance: what have we learned and what do we need to do next?

Transfusion medicine (Oxford, England)·2019
Same journal

Frequent Overactivation of Massive Transfusion Protocol: An Underrecognized Challenge for Blood Resource Stewardship.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Albumin priming enables safe and effective red blood cell exchange in low-weight children with sickle cell disease.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Catastrophic CD34+ autologous hematopoietic stem cell collection despite sustained mobilization and solutions to rescue the harvests.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Title of the study: Corrected Count Increment as a Predictor of Early Graft Dysfunction and Mortality Following Living Donor Liver Transplantation.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

TLR4/MD-2 complex promotes transfusion-related acute lung injury pathogenesis through the activation of the AP-1 and NF-κB signaling pathways.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

The Strategic Utility of Cryopreserved Platelets in Outer Space.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
See all related articles

This study introduces a gene therapy approach using the herpes-simplex thymidine-kinase (HS-tk) suicide gene to control graft-versus-host disease (GVHD) after stem cell transplants, while preserving the graft-versus-leukemia (GVL) effect.

Area of Science:

  • Immunology
  • Gene Therapy
  • Hematopoietic Stem Cell Transplantation

Context:

  • Allogeneic stem cell transplantation often requires T-lymphocyte depletion to prevent graft-versus-host disease (GVHD).
  • However, T-cell depletion increases graft rejection and diminishes the graft-versus-leukemia (GVL) effect.
  • A method for selective T-cell depletion in vivo is needed.

Purpose:

  • To develop a method for selective in vivo T-cell depletion using a suicide gene (HS-tk) delivered via retroviral vectors.
  • To assess the safety and efficacy of gene-modified T-cells in patients undergoing allogeneic hematopoietic stem cell transplantation.

Summary:

  • Retroviral transfer of the HS-tk suicide gene into T-lymphocytes enables their selective depletion with ganciclovir (GCV) in vivo.

Related Experiment Videos

  • Gene-modified T-cells showed specific inhibition by GCV without bystander effects.
  • A Phase I clinical trial is evaluating escalating doses of HS-tk T-cells in HLA-identical recipients, monitoring toxicity, survival, and GCV sensitivity.

    • Impact:

    • This approach aims to mitigate GVHD while preserving the GVL effect, potentially improving outcomes for stem cell transplant recipients.
    • Successful implementation could offer a safer alternative to current T-cell depletion strategies.
    • Further clinical evaluation will determine the therapeutic potential of this gene-modified T-cell strategy.